EASD 2025
The GLP1-Receptor Agonist Semaglutide As an Adjunct to a Lifestyle Intervention in the Treatment of Type 2 Diabetes: Effects on Glucose Metabolism
The trial study was presented on Monday, September 15th, 2025 at the EASD Congress 2025 by Drs J. H. Haltia,
December 22, 2025